CytomX raises $234.4M in stock and warrant sale

CytomX Therapeutics completed an underwritten equity financing built around a large common stock and warrant sale.

Rhea-AI Filing Summary

CytomX Therapeutics completed an underwritten equity financing built around a large common stock and warrant sale. The company issued 45,990,567 shares of common stock at $5.30 per share and pre-funded warrants to purchase 1,179,245 shares at $5.29999 per warrant, with underwriters holding a 30-day option to buy up to 7,075,471 additional shares at the public price.

The transaction closed on March 19, 2026 and is expected to generate approximately $234.4 million in net proceeds after underwriting discounts and expenses. CytomX plans to use the cash to continue developing Varseta-M, advance other pipeline programs, and for general corporate and working capital purposes.

Insights

Biotech capital markets analyst

CytomX raises about $234.4M to fund Varseta-M and its pipeline.

CytomX Therapeutics executed a sizeable underwritten equity deal, selling 45,990,567 common shares plus pre-funded warrants for 1,179,245 shares at roughly the same price point. Underwriters also received a 30-day option for up to 7,075,471 additional shares, which can incrementally expand the raise.

Net proceeds are estimated at $234.4 million, earmarked for continued development of Varseta-M, other pipeline programs, and general corporate and working capital uses. This strengthens the cash position but comes via equity and pre-funded warrants, so the ultimate impact for shareholders depends on the company’s execution on these R&D investments.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CytomX Therapeutics (CTMX) announce in this 8-K filing?

CytomX announced it completed an underwritten offering of common stock and pre-funded warrants, raising an estimated $234.4 million in net proceeds. The capital will support development of Varseta-M, other pipeline programs, and general corporate and working capital needs.

How much capital did CytomX (CTMX) raise in the new stock and warrant offering?

CytomX expects to receive approximately $234.4 million in net proceeds from the transaction. This figure is after deducting underwriting discounts, commissions, and estimated offering expenses, providing substantial funding to advance its clinical pipeline and support ongoing operating requirements.

How many CytomX (CTMX) shares and warrants were sold in the offering?

The company sold 45,990,567 shares of common stock at $5.30 per share and issued pre-funded warrants to purchase 1,179,245 shares at $5.29999 each. Underwriters also received a 30-day option to buy up to 7,075,471 additional shares.

What will CytomX (CTMX) use the $234.4 million in net proceeds for?

CytomX plans to use the net proceeds primarily for continued development of Varseta-M and other pipeline programs. Remaining funds are allocated to general corporate purposes and working capital needs, supporting operations and future research activities.

Who underwrote CytomX Therapeutics (CTMX) latest equity offering?

The offering was underwritten by Jefferies LLC, Piper Sandler & Co., and Cantor Fitzgerald & Co., acting as representatives of several underwriters. Their agreement included a standard 30-day option to purchase additional CytomX common shares at the public offering price.

Under which registration statement did CytomX (CTMX) conduct this offering?

The transaction was conducted under a Form S-3 shelf registration statement with Registration No. 333-294342. It used the base prospectus in that registration and a specific prospectus supplement dated March 17, 2026 to set the terms of this offering.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/19/2026 - 04:05 PM Learn about SEC filing dates

false 0001501989 0001501989 2026-03-17 2026-03-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 17, 2026

CYTOMX THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-37587		27-3521219
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

151 Oyster Point Blvd
Suite 400
South San Francisco, California		94080
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (650) 515-3185

Former Name or Former Address, if Changed Since Last Report: N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value per share		CTMX		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On March 17, 2026, CytomX Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), in connection with the offering, issuance and sale by the Company of 45,990,567 shares of the Company’s common stock, $0.00001 par value per share (the “Common Stock”), at an offering price of $5.30 per share, and pre-funded warrants to purchase 1,179,245 shares of Common Stock (the “Pre-Funded Warrants”) at a price of $5.29999 per Pre-Funded Warrant.

In addition, under the terms of the Underwriting Agreement, the Company granted the Underwriters the option, for 30 days, to purchase up to 7,075,471 additional shares of Common Stock at the public offering price.

The offering was made pursuant to a registration statement on Form S-3 (Registration No. 333-294342) filed on March 16, 2026, including a base prospectus contained therein, and a prospectus supplement dated March 17, 2026. On March 19, 2026, the offering closed and the Company completed the sale and issuance of an aggregate of 45,990,567 shares of Common Stock and Pre-Funded Warrants to purchase 1,179,245 shares of Common Stock.

The Company estimates the net proceeds from the offering will be approximately $234.4 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds of the offering for the continued development of Varseta-M and other pipeline programs, as well as general corporate purposes and working capital needs.

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions.

The foregoing descriptions of the Underwriting Agreement and the Pre-Funded Warrants are not complete and are qualified in their entirety by reference to the full text of the Underwriting Agreement and form of Pre-Funded Warrant, copies of which are filed as Exhibits 1.1 and 4.1 to this Current Report on Form 8-K, respectively, and are incorporated by reference herein.

Latham & Watkins LLP, counsel to the Company, has issued an opinion regarding the validity of the foregoing securities offered and sold in the offering, a copy of which is filed a Exhibit 5.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
1.1		Underwriting Agreement, dated as of March 17, 2026, among CytomX Therapeutics, Inc. and Jefferies LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein.
4.1		Form of Pre-Funded Warrant.
5.1		Opinion of Latham & Watkins LLP.
23.1		Consent of Latham & Watkins LLP (included in Exhibit 5.1).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 19, 2026				CYTOMX THERAPEUTICS, INC.
				By:		/s/ Christopher W. Ogden
						Christopher W. Ogden
						SVP, Chief Financial Officer

Filing Exhibits & Attachments

6 documents

Other Documents

• EX-1.1 EX-1.1 269.5 KB
• EX-4.1 EX-4.1 75.3 KB
• EX-5.1 EX-5.1 19.2 KB
• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB